In NeuT+ mice, Apelin ablation combined with sunitinib treatment significantly increased survival and reduced the tumor burden compared with either intervention alone (Fig 3A and B); blocking Apelin almost doubled the survival of sunitinib‐treated mice and tripled the survival compared to control untreated mice (Fig 3A). This evidence concerns the gene APLN and neoplasm.